Active lytic infection of human primary tonsillar B cells by KSHV and its noncytolytic control by activated CD4+ T cells.

Kaposi sarcoma-associated herpesvirus (KSHV) is a B-lymphotropic virus whose primary site of replication is the oropharynx. KSHV can infect both T and B cells from primary tonsillar explant cultures. However, T cells do not support lytic replication, while B cells spontaneously produce substantial amounts of infectious virus. Here, we provide evidence for a mechanism by which activated T cells may promote or stabilize latency of KSHV infection in B cells. When mixed cultures of B cells and activated T cells were exposed to KSHV, little spontaneous virus production was observed. Removing T cells from the mix or treating the mixed culture with immune suppressants enhanced virus production. Adding back activated T cells to purified infected B cells efficiently suppressed KSHV production, primarily due to CD4(+) T cells. This suppressive activity required T cell activation and direct cell-cell contact, but not prior exposure to KSHV antigen. Suppression was not MHC restricted and did not result in killing of the target cell. We therefore propose that oropharyngeal T cells activated by a variety of stimuli can recognize ligands on infected target B cells, leading to signaling events that prevent spontaneous lytic activation and promote latent infection in this compartment.

[1]  D. Ganem,et al.  Infection of primary human tonsillar lymphoid cells by KSHV reveals frequent but abortive infection of T cells. , 2011, Virology.

[2]  D. Ganem,et al.  Array-Based Transcript Profiling and Limiting-Dilution Reverse Transcription-PCR Analysis Identify Additional Latent Genes in Kaposi's Sarcoma-Associated Herpesvirus , 2010, Journal of Virology.

[3]  T. Seo,et al.  Centrifugal enhancement of Kaposi's sarcoma-associated virus infection of human endothelial cells in vitro. , 2008, Journal of virological methods.

[4]  D. Ganem,et al.  Effects of NFkappaB activation on KSHV latency and lytic reactivation are complex and context-dependent. , 2008, Virology.

[5]  C. Rinaldo,et al.  Human Herpesvirus 8 Infects and Replicates in Primary Cultures of Activated B Lymphocytes through DC-SIGN , 2008, Journal of Virology.

[6]  W. Greene,et al.  Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation , 2006, The Journal of experimental medicine.

[7]  J. Webster-Cyriaque,et al.  Oral EBV and KSHV Infection in HIV , 2006, Advances in dental research.

[8]  D. Ganem,et al.  KSHV infection and the pathogenesis of Kaposi's sarcoma. , 2006, Annual review of pathology.

[9]  N. Perico,et al.  Cyclosporine Formulation and Kaposi’s Sarcoma after Renal Transplantation , 2005, Transplantation.

[10]  A. Rickinson,et al.  Regression of Epstein-Barr Virus-Induced B-Cell Transformation In Vitro Involves Virus-Specific CD8+ T Cells as the Principal Effectors and a Novel CD4+ T-Cell Reactivity , 2005, Journal of Virology.

[11]  J. Vieira,et al.  Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. , 2004, Virology.

[12]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[13]  P. Pellett,et al.  Comparison of human herpesvirus 8 and Epstein–Barr virus seropositivity among children in areas endemic and non‐endemic for Kaposi's sarcoma , 2004, Journal of medical virology.

[14]  J. Levy The search for the CD8+ cell anti-HIV factor (CAF). , 2003, Trends in immunology.

[15]  J. Goedert,et al.  Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma , 2003, AIDS.

[16]  D. Ganem,et al.  Host Range of Kaposi's Sarcoma-Associated Herpesvirus in Cultured Cells , 2003, Journal of Virology.

[17]  P. Stewart,et al.  Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. , 2002, The Journal of infectious diseases.

[18]  Shou-Jiang Gao,et al.  Efficient Infection by a Recombinant Kaposi's Sarcoma-Associated Herpesvirus Cloned in a Bacterial Artificial Chromosome: Application for Genetic Analysis , 2002, Journal of Virology.

[19]  F. Chisari,et al.  Blocking Chemokine Responsive to γ–2/Interferon (IFN)-γ Inducible Protein and Monokine Induced by IFN-γ Activity In Vivo Reduces the Pathogenetic but not the Antiviral Potential of Hepatitis B Virus–specific Cytotoxic T Lymphocytes , 2001, The Journal of experimental medicine.

[20]  M Roederer,et al.  HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. , 2001, Immunity.

[21]  C. Hillyer Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection , 2001 .

[22]  F. Chisari,et al.  Characterization of Nuclear RNases That Cleave Hepatitis B Virus RNA near the La Protein Binding Site , 2001, Journal of Virology.

[23]  B. Chandran,et al.  Activation of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Lytic Replication by Human Cytomegalovirus , 2001, Journal of Virology.

[24]  A. Wald,et al.  Mucosal shedding of human herpesvirus 8 in men. , 2000, The New England journal of medicine.

[25]  J. Levy,et al.  The restricted cellular host range of human herpesvirus 8 , 2000, AIDS.

[26]  M. Corbellino,et al.  Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. , 2000, The American journal of pathology.

[27]  P. Monini,et al.  Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. , 1999, Blood.

[28]  C. Pellet,et al.  Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d' Ile de France (GCIF). , 1999, Transplantation.

[29]  R. Sun,et al.  Cellular Tropism and Viral Interleukin-6 Expression Distinguish Human Herpesvirus 8 Involvement in Kaposi’s Sarcoma, Primary Effusion Lymphoma, and Multicentric Castleman’s Disease , 1999, Journal of Virology.

[30]  E. van Marck,et al.  Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Palestine,et al.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. , 1999, The New England journal of medicine.

[32]  F. Chisari,et al.  Hepatitis B Virus RNA-Binding Proteins Associated with Cytokine-Induced Clearance of Viral RNA from the Liver of Transgenic Mice , 1999, Journal of Virology.

[33]  D. Ganem,et al.  Limited Transmission of Kaposi’s Sarcoma-Associated Herpesvirus in Cultured Cells , 1998, Journal of Virology.

[34]  F. Chisari,et al.  Inhibition of Hepatitis B Virus Replication during Adenovirus and Cytomegalovirus Infections in Transgenic Mice , 1998, Journal of Virology.

[35]  F. Chisari,et al.  Interleukin-12 inhibits hepatitis B virus replication in transgenic mice , 1997, Journal of virology.

[36]  J. Russo,et al.  Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Bell,et al.  Large clonal expansions of CD8+ T cells in acute infectious mononucleosis , 1996, Nature Medicine.

[38]  J. Lieberman,et al.  The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients , 1996, The Journal of experimental medicine.

[39]  G. Boiteau,et al.  J. Virol. Methods , 1996, Journal of Virological Methods.

[40]  F. Chisari,et al.  Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Rafii,et al.  Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells , 1996, The Journal of experimental medicine.

[42]  J. Levy,et al.  Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. , 1996, Immunology today.

[43]  I. Penn,et al.  Sarcomas in organ allograft recipients. , 1995, Transplantation.

[44]  E. Cesarman,et al.  In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. , 1995, Blood.

[45]  F. Sigaux,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. , 1995, Blood.

[46]  E. Cesarman,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. , 1995, The New England journal of medicine.

[47]  P. Moore,et al.  Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and those without HIV infection. , 1995, The New England journal of medicine.

[48]  J. Ambroziak,et al.  Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. , 1995, Science.

[49]  V. Calvez,et al.  Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma , 1995, The Lancet.

[50]  J. Levy,et al.  CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[51]  E. Cesarman,et al.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. , 1994, Science.

[52]  J. Levy,et al.  Effect of cytokines on HIV replication in CD4+ lymphocytes: lack of identity with the CD8+ cell antiviral factor. , 1994, Cellular immunology.

[53]  O. Chilson,et al.  Mitogenic lectins bind to the antigen receptor on human lymphocytes , 1989, European journal of immunology.

[54]  M. Zutter,et al.  Epstein-Barr virus lymphoproliferation after bone marrow transplantation. , 1988, Blood.

[55]  B. Burke,et al.  Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. , 1988, Blood.

[56]  P. Lipsky,et al.  Differential ability of fixed antigen-presenting cells to stimulate nominal antigen-reactive and alloreactive T4 lymphocytes. , 1986, Journal of immunology.

[57]  I. Ernberg,et al.  Effect of cyclosporin‐A (CsA) on the ability of T lymphocyte subsets to inhibit the proliferation of autologous EBV‐transformed B cells , 1985, International journal of cancer.

[58]  M. Crumpton,et al.  Phaseolus vulgaris phytohaemagglutinin (PHA) binds to the human T lymphocyte antigen receptor. , 1984, The EMBO journal.

[59]  J. Oppenheim,et al.  Antigen presentation by human monocytes: evidence for stimulant processing and requirement for interleukin 1. , 1983, Journal of immunology.

[60]  S. McLachlan,et al.  Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein–Barr virus-induced B-cell lines , 1981, Nature.

[61]  J. H. Pope,et al.  Long‐term T‐cell‐mediated immunity to epstein‐barr virus in man. IV. Development of T‐cell memory in convalescent infectious mononucleosis patients , 1980, International journal of cancer.

[62]  J. H. Pope,et al.  Long‐term T‐cell‐mediated immunity to Epstein‐Barr virus in man. III. Activation of cytotoxic T cells in virus‐infected leukocyte cultures , 1979, International journal of cancer.

[63]  J. H. Pope,et al.  Long‐term T‐cell‐mediated immunity to Epstein‐Barr virus in man. II. Components necessary for regression in virus‐infected leukocyte cultures , 1979 .

[64]  F. Chisari,et al.  Noncytolytic control of viral infections by the innate and adaptive immune response. , 2001, Annual review of immunology.

[65]  C. Pellet,et al.  Human herpes virus-8 and other risk factors for Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de Transplantation d' Ile de France (GCIF). , 1999, Transplantation.